Glucose-Lowering Medications and Angina Burden in Patients with Stable Coronary Disease: results from the Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina (TERISA) Trial.
暂无分享,去创建一个
J. Spertus | B. Chaitman | Darren K Mcguire | S. Arnold | S. Inzucchi | M. Kosiborod | L. Belardinelli | F. Tang | Patrick Yue
[1] J. Spertus,et al. Association between diabetes mellitus and angina after acute myocardial infarction: analysis of the TRIUMPH prospective cohort study , 2015, European journal of preventive cardiology.
[2] Deepak L. Bhatt,et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. , 2013, The New England journal of medicine.
[3] Craig Wilson,et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. , 2013, The New England journal of medicine.
[4] J. Spertus,et al. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). , 2013, Journal of the American College of Cardiology.
[5] R. Wender,et al. Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2013, Diabetologia.
[6] Marc Evans,et al. Mortality and Other Important Diabetes-Related Outcomes With Insulin vs Other Antihyperglycemic Therapies in Type 2 Diabetes , 2013, The Journal of clinical endocrinology and metabolism.
[7] Harshal R. Patil,et al. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. , 2012, The American journal of cardiology.
[8] D. Matthews,et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach , 2012, Diabetes Care.
[9] F. Gueyffier,et al. Reappraisal of Metformin Efficacy in the Treatment of Type 2 Diabetes: A Meta-Analysis of Randomised Controlled Trials , 2012, PLoS medicine.
[10] A. Vaag,et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. , 2011, European heart journal.
[11] L. Rydén,et al. Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin–Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study , 2011, Diabetologia.
[12] R. Heine,et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study , 2010, The Lancet.
[13] Darren K Mcguire,et al. Cardiovascular disease and type 2 diabetes mellitus: Regulating glucose and regulating drugs , 2009, Current cardiology reports.
[14] E. Braunwald,et al. Economic Impact of Angina After an Acute Coronary Syndrome: Insights From the MERLIN-TIMI 36 Trial , 2009, Circulation. Cardiovascular quality and outcomes.
[15] C. Mogensen,et al. Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study. , 2008, Diabetes research and clinical practice.
[16] Diederick Grobbee,et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.
[17] R. Nesto,et al. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials , 2007, The Lancet.
[18] K. Wolski,et al. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.
[19] I. Konstantinov,et al. Intermittent peripheral tissue ischemia during coronary ischemia reduces myocardial infarction through a KATP-dependent mechanism: first demonstration of remote ischemic perconditioning. , 2007, American journal of physiology. Heart and circulatory physiology.
[20] R. Brook,et al. Quality of life of patients with chronic stable angina before and four years after coronary revascularisation compared with a normal population , 2002, Heart.
[21] J R Hampton,et al. Quality of life four years after acute myocardial infarction: short form 36 scores compared with a normal population , 1999, Heart.
[22] R. Holman,et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .
[23] G. Knatterud,et al. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. 3. Clinical implications of UGDP results. , 1971, JAMA.
[24] J. Spertus,et al. Bmc Cardiovascular Disorders the Impact of Diabetes on One-year Health Status Outcomes following Acute Coronary Syndromes , 2022 .